The CONTINUOUS MICRODOSING™ Delivery System delivers continuous treatment for persistent DME

ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg was engineered to continuously and consistently treat diabetic macular edema (DME) for up to 36 months1

Starting at day 1, ILUVIEN delivers a continuous therapeutic submicrogram dose of inflammation-suppressing fluocinolone acetonide (FAc) for up to 3 years1,2

Aqueous levels of FAc after injecting ILUVIEN in human eyes (n=12)2

These data were generated using an assay validated for human plasma.

ILUVIEN is a corticosteroid treatment for diabetic macular edema (DME)

Corticosteroids inhibit inflammatory responses to a variety of inciting agents, including multiple inflammatory cytokines. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.

Watch the ILUVIEN CONTINUOUS MICRODOSING™ Delivery System mechanism of action video

Review efficacy data from the ILUVIEN
Phase 3 clinical trials.


Real-world data from the USER Study support the benefits of CONTINUOUS MICRODOSING Delivery with ILUVIEN.3